NSE: AJANTPHARM | BSE: 532331

Mid-range Performer

Download real time

2706.40 22.20 (0.83%)

156.2K NSE+BSE Volume

NSE 21 Jan, 2026 12:40 PM (IST)

33,806.2

Market Cap

High in industry

Beta 1Year

Very Low volatility

Board Meeting

The next board meeting for Ajanta Pharma is on 30 Jan 2026 for the purpose of Quarterly Results See details

Ajanta Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AJANTPHARM, BSE:532331 Ajanta Pharma Ltd.

Search Inside the pdf :

Ajanta Pharma Ltd.

29 Dec 2025

2706.40

0.83%

Branded generics playbook fires; semaglutide adds a new growth leg

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

AJP is implementing multiple strategic initiatives across focus branded generics markets of India, Asia, and Africa to sustain robust industry outperformance.

Ajanta Pharma Ltd. is trading above its 200 day SMA of 2599.0

Ajanta Pharma Ltd.

04 Nov 2025

2706.40

0.83%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

Target

ICICI Direct

Q2FY26- Momentum driven by US and India Business - Revenues grew ~14% YoY to 1354 crore driven by US and India branded business which grew ~48% / ~12% to 344 crore and 432 crore, respectively. Other branded businesses such as Asia and Africa witnessed the growth of 5% / 4% (on higher base) to 310 crore and 221 crore, respectively. On the operational front, EBITDA grew 5.4% YoY to ~328 crore (excluding forex losses of 41 crore, 9 % growth to ~369 crore) with margins at 24.2%...

Ajanta Pharma Ltd. has an average target of 2963.33 from 6 brokers.

Ajanta Pharma Ltd.

03 Nov 2025

2706.40

0.83%

In-line 2Q; growth led by DF/US generics

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Ajanta Pharma (AJP)’s 2QFY26 revenue was slightly above our expectation (3.5% beat). EBITDA and PAT were largely in line and grew at a lower rate compared to revenue growth for the quarter.

Ajanta Pharma Ltd. is trading above its 200 day SMA of 2599.0

Ajanta Pharma Ltd.

19 Sep 2025

2706.40

0.83%

Ajanta Pharma (AJP IN) Company Initiation Leveraging BGx...

Buy: Ajanta Pharma Ltd.

Prabhudas Lilladhar

Promoters pledged 2.01% of shares in last quarter. Total pledge stands at 17.29% of promoter holdings

Ajanta Pharma Ltd.

16 Jun 2025

2706.40

0.83%

BP Equities Ajanta Pharma Ltd. Shining Star Series BUY Target 3,140

Buy: Ajanta Pharma Ltd.

BP Wealth

Ajanta Pharma Ltd. is trading above its 200 day SMA of 2599.0

Ajanta Pharma Ltd.

01 May 2025

2706.40

0.83%

Ajanta Pharma (HOLD): A New Dawn of Culture

Hold: Ajanta Pharma Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Mix set of earnings where sales/EBITDA/PAT reported 5%/3%/10% above estimates; EBITDA margin reported 60 bps below estimates

Ajanta Pharma Ltd. has an average target of 2963.33 from 6 brokers.

Ajanta Pharma Ltd.

01 May 2025

2706.40

0.83%

Elevated cost to keep a check on margins

Sell: Ajanta Pharma Ltd.

Recommendation Target

ICICI Securities Limited

Ajanta Pharma’s Q4FY25 result was in line with our expectations. Revenue growth of 11% YoY was primarily driven by India and US businesses while Africa institutional biz continues to be a drag (-54.1% YoY).

Ajanta Pharma Ltd. is trading below its 30 day SMA of 2720.2

Ajanta Pharma Ltd.

31 Jan 2025

2706.40

0.83%

Ajanta Pharma (SELL): Entering newer therapies to result in higher costs

Sell: Ajanta Pharma Ltd.

Target

BOB Capital Markets Ltd.

AJP reported in-line earnings, sales were 3.6% below estimates, while EBITDA/PAT reported 1%/3% above our estimates

Ajanta Pharma Ltd. is trading below its 30 day SMA of 2720.2

Ajanta Pharma Ltd.

30 Jan 2025

2706.40

0.83%

India/Asia drive earnings

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Ajanta Pharma (AJP) delivered a marginally better-than-expected performance in 3QFY25. It has continued to outperform in the Domestic Formulation (DF) market during this quarter.